Transcription-Mediated Amplification Detects Biopharmaceutic Microbial Contamination

Real-time transcription-mediated amplification (TMA) technology detects targeted microbial contamination within hours compared to the days or weeks usually required to generate results using traditional culture-based technology.

Faster detection allows biopharmaceutic manufacturers to take corrective action earlier in the production process, which reduces downstream processing risks, optimizes product yields, and improves final product quality. These improvements result in better operational efficiency and lower manufacturing cost for product manufacturers.

The MilliProbe TMA technology combines Millipore's (Billerica, MA, USA) sample preparation methodologies with Gen-Probe's (San Diego, CA, USA) advanced nucleic acid technologies to deliver both speed and sensitivity in one microbial screening tool.

Building on the technological innovation of the initial MilliProbe assay detection of Pseudomonas aeruginosa in purified water used during drug production, Millipore and Gen-Probe have continued to develop new assays for additional contaminants. These assays provide further significant improvements in speed, sensitivity, and specificity and incorporate sample preparation innovations that allow real-time TMA technology to be applied to more challenging biopharmaceutic applications and to target microorganisms.

Gen-Probe develops, manufactures, and markets rapid, accurate, and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood.

Millipore is a provider of products and services that improve productivity in life science laboratories and bioprocessing manufacturing sites.


Related Links:
Millipore
Gen-Probe